GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (LTS:0QIU) » Definitions » Cyclically Adjusted FCF per Share

Novo Nordisk A/S (LTS:0QIU) Cyclically Adjusted FCF per Share : kr9.66 (As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Novo Nordisk A/S Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Novo Nordisk A/S's adjusted free cash flow per share for the three months ended in Mar. 2024 was kr1.187. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is kr9.66 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Novo Nordisk A/S's average Cyclically Adjusted FCF Growth Rate was 7.30% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 17.50% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 14.30% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 15.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Novo Nordisk A/S was 21.60% per year. The lowest was 8.40% per year. And the median was 16.20% per year.

As of today (2024-05-14), Novo Nordisk A/S's current stock price is kr893.15. Novo Nordisk A/S's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was kr9.66. Novo Nordisk A/S's Cyclically Adjusted Price-to-FCF of today is 92.46.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Novo Nordisk A/S was 95.52. The lowest was 27.84. And the median was 46.29.


Novo Nordisk A/S Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Novo Nordisk A/S's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Cyclically Adjusted FCF per Share Chart

Novo Nordisk A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.54 5.88 6.63 8.36 9.47

Novo Nordisk A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.84 9.11 9.97 9.47 9.66

Competitive Comparison of Novo Nordisk A/S's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Novo Nordisk A/S's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk A/S's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novo Nordisk A/S's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Novo Nordisk A/S's Cyclically Adjusted Price-to-FCF falls into.



Novo Nordisk A/S Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novo Nordisk A/S's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.187/116.7000*116.7000
=1.187

Current CPI (Mar. 2024) = 116.7000.

Novo Nordisk A/S Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 1.372 99.700 1.606
201409 2.119 99.700 2.480
201412 1.107 99.400 1.300
201503 0.635 100.200 0.740
201506 2.097 100.300 2.440
201509 2.099 100.200 2.445
201512 1.362 99.800 1.593
201603 1.242 100.200 1.447
201606 2.507 100.600 2.908
201609 2.486 100.200 2.895
201612 1.667 100.300 1.940
201703 2.077 101.200 2.395
201706 1.713 101.200 1.975
201709 2.211 101.800 2.535
201712 0.569 101.300 0.656
201803 1.404 101.700 1.611
201806 2.717 102.300 3.099
201809 1.800 102.400 2.051
201812 0.713 102.100 0.815
201903 1.434 102.900 1.626
201906 2.572 102.900 2.917
201909 3.000 102.900 3.402
201912 0.465 102.900 0.527
202003 1.760 103.300 1.988
202006 4.882 103.200 5.521
202009 2.445 103.500 2.757
202012 -2.738 103.400 -3.090
202103 2.107 104.300 2.357
202106 5.067 105.000 5.632
202109 4.314 105.800 4.758
202112 -1.162 106.600 -1.272
202203 4.775 109.900 5.070
202206 4.698 113.600 4.826
202209 4.411 116.400 4.422
202212 0.205 115.900 0.206
202303 5.542 117.300 5.514
202306 4.784 116.400 4.796
202309 6.759 117.400 6.719
202312 -1.539 116.700 -1.539
202403 1.187 116.700 1.187

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Novo Nordisk A/S  (LTS:0QIU) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Novo Nordisk A/S's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=893.15/9.66
=92.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Novo Nordisk A/S was 95.52. The lowest was 27.84. And the median was 46.29.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Novo Nordisk A/S Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk A/S (LTS:0QIU) Business Description

Industry
Address
Novo Alle 1, Bagsvaerd, DNK, DK-2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk A/S (LTS:0QIU) Headlines

No Headlines